Agios Pharmaceuticals, Inc. (AGIO) Research

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Market snapshot

Symbol
AGIO
Price
$34.16
Day change
+3.26%
Market cap
$2.0B
P/E ratio
-4.75x
52-week range
22.24-46
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$43.33

Recent news

  • Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib

    Agios Pharmaceuticals (NASDAQ:AGIO) has secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor, under a licensing agreement with South Korea's Oscotec, the company said Monday. The agreement gives Agios worldwide rights to develop and commercialize cevidoplenib, which the company described as a novel, next-generation oral inhibitor of spleen tyrosine kinase (SYK).

  • Agios scraps blood cancer drug program after study miss

    Agios Pharmaceuticals said on Friday ​it will stop developing its ‌experimental drug for a form of blood cancer after a ​mid-stage trial failed to ​show enough benefit.

Peer companies

  • Beam Therapeutics Inc. (BEAM)
  • Cogent Biosciences, Inc. (COGT)
  • Denali Therapeutics Inc. (DNLI)
  • 89bio, Inc. (ETNB)
  • Galapagos N.V. (GLPG)
  • ImmunityBio, Inc. (IBRX)
  • Liquidia Corporation (LQDA)
  • Arcus Biosciences, Inc. (RCUS)

Recent insider activity

  • Owen Adams Catherine — M-Exempt (1976 shares) on 2026-06-13
  • Owen Adams Catherine — M-Exempt (1976 shares) on 2026-06-13
  • CAPELLO JEFFREY D — M-Exempt (1976 shares) on 2026-06-13
  • CAPELLO JEFFREY D — M-Exempt (1976 shares) on 2026-06-13
  • Burns James William — M-Exempt (8500 shares) on 2026-04-02

Open Agios Pharmaceuticals, Inc. (AGIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.